Rampart Skin Graft: Clinical Guide for Wound Care Clinicians

Rampart Skin Graft is an amniotic membrane allograft that has emerged as a significant option in the advanced wound care arsenal. For clinicians managing chronic wounds, diabetic foot ulcers, and complex surgical sites, understanding when to select Rampart, how to apply it correctly, and what outcomes to expect is essential for optimizing patient care and navigating reimbursement.

This guide synthesizes the clinical evidence, application techniques, and practical considerations for using Rampart Skin Graft in contemporary wound care practice. For broader context on how amniotic products compare to synthetic alternatives, see our amniotic membrane vs synthetic graft comparison.

What Rampart Skin Graft Is and How It Works

Rampart Skin Graft is a dehydrated human amniotic membrane allograft processed to retain the biological activity of the native tissue while providing a stable, shelf-stable graft for clinical use. The product is derived from donated placental tissue and, like other 361 HCT/P amniotic membrane products, is regulated under Section 361 of the Public Health Service Act and 21 CFR Part 1271: minimally manipulated, donor-screened human tissue for homologous use as a wound covering. This regulatory framework governs tissue safety and handling — it is not a premarket efficacy approval, and clinical selection should rest on the class-level evidence summarized in the outcomes section, not on the regulatory pathway alone.

The mechanism of action is multifaceted. Amniotic membrane has been characterized as containing a collagen-rich extracellular matrix (including collagen types I, III, IV, V, and VII) with fibronectin, laminin, and proteoglycans, together with growth factors and cytokines associated with tissue repair — including VEGF, FGF-2, EGF, PDGF, and TGF-beta — though retained concentrations vary by processing method and product (reviewed in PMC12316762).

These growth factors modulate the wound microenvironment in three critical ways. First, they stimulate angiogenesis, bringing oxygen and nutrients to hypoxic wound beds. Second, they recruit fibroblasts and keratinocytes, accelerating the proliferative phase of healing. Third, they modulate inflammation through anti-inflammatory cytokines like interleukin-1 receptor antagonist (IL-1ra) and tissue inhibitors of metalloproteinases (TIMPs), breaking the chronic inflammation cycle that stalls so many wounds.

Indications and Appropriate Patient Selection

Rampart Skin Graft is indicated for wounds that have stalled despite optimal standard care. The typical patient profile includes:

• Diabetic foot ulcers (DFUs) that have not achieved 50% area reduction after 4 weeks of standard care, including offloading, debridement, and moist wound healing.
• Venous leg ulcers (VLUs) with persistent fibrinous wound beds, excessive exudate, or failure to progress toward epithelialization despite compression therapy.
• Surgical wounds with compromised healing due to radiation, poor vascularity, or patient comorbidities such as immunosuppression or malnutrition.
• Partial-thickness burns where accelerated re-epithelialization reduces infection risk and improves cosmetic outcomes.
• Traumatic wounds with significant tissue loss where granulation tissue formation is delayed.

Patient selection also requires attention to contraindications and cautions. Active infection should be controlled before application. Amniotic membrane contains native antimicrobial and anti-inflammatory components (PMID 32580594), but product-specific retention varies and is not a substitute for infection control. Severe peripheral arterial disease with inadequate perfusion will compromise graft viability regardless of biological activity — commonly cited exclusion thresholds in advanced-wound-care protocols include ABI less than 0.5 or toe pressures below 30 mmHg, but align your specific cutoffs with institutional policy and the vascular assessment rather than treating any single number as absolute. Patients with known hypersensitivity to human-derived tissue products should not receive amniotic allografts.

Application Technique: Step by Step

Proper application is critical to outcomes. The graft must contact viable wound bed tissue to exert its biological effects. Application over necrotic tissue, thick eschar, or heavy slough will produce disappointing results.

Step 1: Wound Bed Preparation

Sharp debridement is the foundation. Remove all non-viable tissue until punctate bleeding is observed. For plantar DFUs, this often requires aggressive saucerization to eliminate undermining and expose the true wound dimensions. Biofilm disruption through mechanical debridement combined with antiseptic irrigation reduces microbial load below the critical colonization threshold; chronic wounds frequently harbor biofilm — scanning electron microscopy of chronic-wound specimens visualized biofilm in the majority of cases examined (James et al., PMID 18086294).

Address exudate management before application. Rampart is applied dry and will absorb moderate exudate, but heavily exuding wounds may require a secondary absorbent dressing. For dry wounds, consider hydrating the bed with sterile saline before graft placement.

Step 2: Graft Sizing and Placement

Measure the wound and select a graft size that covers the entire wound bed with a 1-2 mm margin overlap onto periwound skin. The graft should not be stretched or bunched. Gentle contact with the wound surface is the goal.

Remove the graft from its packaging using sterile technique. The dehydrated membrane is fragile when dry but becomes pliable upon hydration with wound exudate or sterile saline. Rampart DL Matrix is a dual-layer, non-side-specific membrane — either surface may contact the wound bed (verify against the product's IFU). For side-specific single-layer membranes, follow the manufacturer's orientation markings.

Step 3: Securing the Graft

Secure the graft with a non-adherent contact layer followed by an appropriate secondary dressing based on exudate level. Options include:

• Low exudate: Non-adherent silicone contact layer with a foam or hydrocolloid secondary dressing.
• Moderate exudate: Non-adherent contact layer with an alginate or superabsorbent foam secondary dressing.
• High exudate: Consider an antimicrobial contact layer (silver or PHMB) with a superabsorbent foam or negative pressure wound therapy (NPWT) overlay.

NPWT over amniotic grafts has been described in case reports and small series, with the negative pressure improving graft contact and exudate removal while the membrane supports granulation. Specific pressure settings over amniotic membrane have not been established in controlled trials; if NPWT is used as an adjunct, follow the device manufacturer's guidelines, the tissue manufacturer's IFU, and local protocol rather than published universal pressure numbers.

Step 4: Offloading and Adjunctive Care

For plantar DFUs, total contact casting (TCC) remains the gold standard for offloading. Removable walker boots are acceptable alternatives if patient compliance is high, but adherence must be verified at each visit. Without effective offloading, even the most biologically active graft will fail.

Continue standard adjunctive care: glycemic control optimization, nutritional assessment and supplementation, smoking cessation support, and vascular assessment with referral for revascularization when indicated.

Step 5: Dressing Changes and Reapplication

The initial dressing should generally remain in place for several days (commonly up to a week) to allow graft incorporation, unless exudate, infection signs, or the secondary dressing's wear time dictate otherwise; follow the manufacturer's IFU and your institutional protocol for the specific interval. At the first dressing change, assess graft integration. The graft may appear dissolved or incorporated into the wound bed. This is expected and does not indicate failure.

Reapplication frequency depends on wound response and is constrained by payer policy: MAC Local Coverage Determinations set application-frequency limits (commonly weekly early in therapy), and the manufacturer's IFU and your MAC's LCD govern the cadence. Reassess trajectory against the 4-week 50%-area-reduction threshold below rather than a fixed application count.

Expected Outcomes and Timeline

Clinical evidence for amniotic membrane allografts, including Rampart, supports specific outcome expectations when patient selection and application technique are appropriate.

Time to 50% area reduction: The validated early-response metric is percent wound-area reduction over the first 4 weeks: in DFUs, ≥50% area reduction at 4 weeks is a robust predictor of complete healing at 12 weeks (Sheehan et al., PMID 12766127). Use this threshold at each visit to judge whether the current regimen — graft plus standard care — is on trajectory, rather than expecting a fixed timeline.

Complete wound closure: Systematic reviews of amniotic membrane allografts in DFUs report improved healing likelihood versus standard care, with pooled analyses of randomized trials finding a significant advantage for human amniotic membrane products over standard wound care (Su et al., PMID 32119765; Mohammed et al., PMID 36104736). These pooled estimates apply to the amniotic membrane class; no published randomized trial evaluates Rampart specifically. Class-level randomized trials of dehydrated amnion/chorion membrane in DFUs are the closest available evidence (e.g., DiDomenico et al., PMID 30019528). For VLUs, randomized evidence supports amnion/chorion membrane plus compression over compression alone (Serena et al., PMID 25224019).

Healing velocity: Rather than tracking informal impressions of weekly speed, judge trajectory by the same validated milestone: ≥50% area reduction by week 4 (Sheehan et al., PMID 12766127, discussed above). A wound meeting that threshold is on a healing trajectory; one that misses it warrants the reassessment triggers below.

Infection: Amniotic membrane contains native antimicrobial and anti-inflammatory components, and controlling wound bioburden remains a prerequisite for graft integration; see the biofilm discussion below. No published trial quantifies an infection-reduction percentage for Rampart specifically.

Reimbursement and Coding

Reimbursement for Rampart Skin Graft varies by payer and setting. Understanding the coding landscape is essential for sustainable practice integration.

Medicare and Commercial Payers

Amniotic membrane products do not share a billing code. Each product carries its own HCPCS Level II Q-code assigned by CMS, and the code billed must match the product actually applied — substituting one amniotic membrane code for another is a common denial and audit trigger. Rampart DL Matrix maps to Q4347 (Rampart DL matrix, per square centimeter). The companion dehydrated membrane in this portfolio, AmnioAMP-MP, maps to Q4250. Under the CY 2026 CMS skin-substitute payment restructuring (CMS-1832-F; Federal Register 2025-19787, as corrected by FR Doc. 2025-21458), product payment for most outpatient amniotic membrane allografts is the standardized flat rate ($127.14/cm²), with the application procedure reported separately under CPT 15271–15278. Product-to-code assignments are published in the CMS HCPCS file (see the Q4347 and Q4250 long descriptors); always verify the product-specific code against the current CMS HCPCS file and your MAC's Local Coverage Determination before submitting claims; for a full cross-product walkthrough, see our wound biologics HCPCS coding and billing reference.

Medicare coverage for skin substitute grafts is governed by local coverage determinations (LCDs) that vary by Medicare Administrative Contractor (MAC). Most LCDs require documentation of:

• Wound duration of at least 4 weeks with documented failure to improve
• Appropriate wound bed preparation (debridement)
• Offloading compliance for plantar wounds
• Regular wound measurements with area calculations
• Progress notes demonstrating response to treatment

Commercial payers may have additional prior authorization requirements. Pre-authorization is strongly recommended before initiating treatment, particularly for plans with high deductibles or limited durable medical equipment coverage.

Documentation Best Practices

Complete documentation protects both patient care and reimbursement. Required elements include:

• Initial wound assessment with measurements (length, width, depth), location, etiology, and duration
• Photographic documentation at baseline and at each visit
• Detailed description of prior treatments and outcomes
• Debridement notes with tissue type removed and wound bed appearance post-debridement
• Graft size applied, lot number, and application date
• Offloading method documented at each visit
• Progress assessment with area reduction calculations

For a deeper dive into reimbursement specifics, see our reimbursement coding guide for amniotic membrane allografts.

Rampart vs Other Amniotic Products

The amniotic membrane market includes multiple products with varying processing methods, preservation techniques, and biological activity profiles. Key differentiators include:

Class-level properties. Storage, shelf-life, and growth-factor specifics vary by product and manufacturer — verify against the manufacturer's current product documentation before procurement or billing decisions.

Feature	Rampart Skin Graft	Other Dehydrated Membranes	Cryopreserved Membranes
Storage	Room temperature	Room temperature	Frozen (ultra-low; exact temperature per product IFU)
Handling	Easy, no thawing	Easy, no thawing	Requires thawing protocol
Payment (CY 2026)	Standardized product rate for most skin substitutes ($127.14/cm² under CMS-1832-F)	Same CY 2026 standardized-rate framework	Same CY 2026 standardized-rate framework

What this table deliberately omits: shelf life and growth-factor retention are product-specific manufacturer specifications, not preservation-class facts — a cryopreserved sheet is not automatically more growth-factor-rich than a dehydrated one. Compare those numbers against each manufacturer's published IFU, not against the category labels above.

The choice between dehydrated and cryopreserved products depends on clinical setting, storage capacity, handling preferences, and cost considerations. Dehydrated products like Rampart offer convenience and shelf stability that make them practical for outpatient clinics and smaller practices. Cryopreserved products offer frozen storage and thaw protocols instead of ambient handling; growth-factor and handling characteristics vary product by product and should be compared against each manufacturer's published specifications rather than assumed from preservation class. For a portfolio-level comparison within the dehydrated category, see our AmnioAMP vs Rampart clinical comparison and the Rampart product overview for verified product specifics.

Common Application Errors and How to Avoid Them

Even experienced clinicians can compromise outcomes with subtle errors in application or patient management.

Inadequate debridement: The most common error is applying the graft over non-viable tissue. If the wound bed does not bleed when gently scraped, it is not ready. Take the time to debride thoroughly.

Skipping offloading: In DFUs, offloading is as important as the graft itself. A biologically active graft under persistent mechanical stress will fail. Document offloading at every visit and verify compliance.

Incorrect graft orientation: For side-specific single-layer membranes, the stromal or basement-membrane side must contact the wound bed — follow the product's orientation markings. Rampart DL Matrix is non-side-specific (either surface may contact the wound bed); confirm orientation requirements against the IFU for whichever product you are applying.

Over-tight dressings: Dressings that compress the graft excessively can compromise blood flow to the wound bed. Secure the graft firmly but not tightly. The goal is contact, not compression.

Premature discontinuation: Some clinicians stop applications at first signs of improvement. Wounds that stall at 70-80% closure often benefit from continued applications until complete epithelialization. Set clear criteria for discontinuation based on wound trajectory, not calendar dates.

Integration Into Practice Workflow

Successful integration of Rampart Skin Graft into clinical practice requires workflow adjustments, not just product knowledge.

Inventory management: Maintain a stock of the sheet and disk sizes your formulary actually uses — available sizes are listed in the manufacturer's current catalog and IFU, so confirm before standardizing par levels. Dehydrated products have long shelf lives, so stock rotation is minimal.

Staff training: All clinical staff involved in wound care should understand indications, contraindications, application technique, and documentation requirements. Consider competency validation for new staff.

Patient education: Patients should understand why they are receiving an advanced biologic, what to expect during treatment, and their role in offloading and wound protection. Written materials improve compliance.

Outcome tracking: Implement a system for tracking wound area reduction, time to closure, and infection rates. This data supports quality improvement, payer negotiations, and clinical decision-making.

The Bottom Line

Rampart Skin Graft represents a practical option for clinicians managing chronic wounds that have stalled despite standard care, with class-level evidence supporting the dehydrated amniotic membrane category (PMIDs 32119765, 36104736). Its ambient handling and room-temperature storage make it suitable for a wide range of clinical settings.

The key to success is not the graft itself but the system around it: proper patient selection, thorough wound bed preparation, effective offloading, consistent application, and meticulous documentation. Amniotic membrane allografts are powerful tools, but they are tools. They require skilled operators and appropriate clinical infrastructure to deliver their full potential.

For clinicians ready to integrate advanced biologics into their wound care practice, Rampart Skin Graft offers a combination of practical handling and reimbursement viability under the CY 2026 flat-rate framework that makes it a candidate for formulary evaluation; weigh it against the class-level evidence and your own MAC's coverage terms.

Rampart Wound Matrix and Rampart Wound Dressing Protocol

Rampart Wound Matrix is the descriptor clinicians use when they search for this product family; the clinical guide above uses the product name Rampart Skin Graft. They refer to the same material. The Rampart wound dressing protocol below is the sequence to follow at the point of care, and the sister page What Is Rampart DL Matrix? Product Overview carries the composition and format detail.

Rampart Wound Dressing Protocol

1. Prepare the wound bed. Debride devitalized tissue, manage infection before application, and establish hemostasis. Measure and document the wound in centimetres at the qualifying visit.
2. Confirm the size. Select the product size to the measured wound surface area. Record the size and quantity used in the operative note.
3. Rehydrate per the Instructions for Use. Follow the current IFU for the specific Rampart configuration; rehydration time and technique are format-specific.
4. Apply with correct orientation. Place the graft per the IFU orientation and ensure full contact with the prepared bed without overlapping beyond the wound margin.
5. Dress and protect. Use a non-adherent contact layer plus a secondary dressing matched to exudate level. Offload or compress according to wound etiology.
6. Schedule reassessment. Set a defined follow-up interval, reassess at each visit, and document response or the absence of it.
7. Capture coding at the point of care. Record the product HCPCS code, the procedure code, and the treated surface area as the application is performed, not retrospectively.

Frequently Asked Questions

Is Rampart Wound Matrix the same product as Rampart Skin Graft?

They are the same material described two ways. Clinicians searching for the wound matrix and the clinical literature describing the skin graft are referring to the same amniotic membrane allograft family. Verify the specific configuration against the current Instructions for Use and the product label before application.

What is the Rampart wound dressing protocol?

Prepare and measure the wound bed, size the product to the measured surface area, rehydrate and apply per the IFU with correct orientation, dress with a non-adherent contact layer and an exudate-matched secondary dressing, offload or compress per etiology, and reassess on a defined schedule with coding captured at the point of care.

How should the treated area be documented for coding?

Record the wound measurements in centimetres at each visit, the treated surface area, the product HCPCS code, and the procedure code on the operative note at the time of application. Under the CY 2026 flat-rate framework the utilisation record is the economic record, so the note must reconcile to the units reported.

---

References

1. Sheehan P, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1719–20. PMID 12766127. https://pubmed.ncbi.nlm.nih.gov/12766127/.
2. Su YN, et al. Human amniotic membrane allograft for chronic diabetic foot ulcers: systematic review and meta-analysis of randomised controlled trials. International Wound Journal. 2020. PMID 32119765. https://pubmed.ncbi.nlm.nih.gov/32119765/.
3. Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers: do they help? Systematic review and meta-analysis. Journal of Foot and Ankle Research. 2022. PMID 36104736. https://pubmed.ncbi.nlm.nih.gov/36104736/.
4. DiDomenico LA, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers. International Wound Journal. 2018. PMID 30019528. https://pubmed.ncbi.nlm.nih.gov/30019528/.
5. Serena TE, et al. Dehydrated human amnion/chorion membrane allografts plus multilayer compression therapy vs. compression alone in venous leg ulcers. Wound Repair and Regeneration. 2014. PMID 25224019. https://pubmed.ncbi.nlm.nih.gov/25224019/.
6. James GA, et al. Biofilms in chronic wounds. Wound Repair and Regeneration. 2008. PMID 18086294. https://pubmed.ncbi.nlm.nih.gov/18086294/.
7. Joshi CJ, et al. Up-to-date role of the dehydrated human amnion/chorion membrane (AMNIOFIX) for wound healing. Expert Opin Biol Ther. 2020. PMID 32580594. https://pubmed.ncbi.nlm.nih.gov/32580594/.